Cargando…
The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study
OBJECTIVE: To assess the efficacy and safety of the novel histone deacetylase inhibitor, chidamide, in combination with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (Chi-CHOEP) for untreated peripheral T-cell lymphoma (PTCL). METHODS: A prospective, multicenter, single arm,...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Compuscript
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330529/ https://www.ncbi.nlm.nih.gov/pubmed/33755379 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0413 |
_version_ | 1783732737784414208 |
---|---|
author | Zhang, Wei Su, Liping Liu, Lihong Gao, Yuhuan Wang, Quanshun Su, Hang Song, Yuhuan Zhang, Huilai Shen, Jing Jing, Hongmei Wang, Shuye Cen, Xinan Liu, Hui Liu, Aichun Li, Zengjun Luo, Jianmin He, Jianxia Wang, Jingwen O’Connor, O. A. Zhou, Daobin |
author_facet | Zhang, Wei Su, Liping Liu, Lihong Gao, Yuhuan Wang, Quanshun Su, Hang Song, Yuhuan Zhang, Huilai Shen, Jing Jing, Hongmei Wang, Shuye Cen, Xinan Liu, Hui Liu, Aichun Li, Zengjun Luo, Jianmin He, Jianxia Wang, Jingwen O’Connor, O. A. Zhou, Daobin |
author_sort | Zhang, Wei |
collection | PubMed |
description | OBJECTIVE: To assess the efficacy and safety of the novel histone deacetylase inhibitor, chidamide, in combination with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (Chi-CHOEP) for untreated peripheral T-cell lymphoma (PTCL). METHODS: A prospective, multicenter, single arm, phase 1b/2 study was conducted. A total of 128 patients with untreated PTCL (18–70 years of age) were enrolled between March 2016 and November 2019, and treated with up to 6 cycles with the Chi-CHOEP regimen. In the phase 1b study, 3 dose levels of chidamide were evaluated and the primary endpoint was determination of the maximum-tolerated dose and recommended phase 2 dose (RP2D). The primary endpoint of the phase 2 study was 2-year progression-free survival (PFS). RESULTS: Fifteen patients were enrolled in the phase 1b study and the RP2D for chidamide was determined to be 20 mg, twice a week. A total of 113 patients were treated at the RP2D in the phase 2 study, and the overall response rate was 60.2%, with a complete response rate of 40.7%. At a median follow-up of 36 months, the median PFS was 10.7 months, with 1-, 2-, and 3-year PFS rates of 49.9%, 38.0%, and 32.8%, respectively. The Chi-CHOEP regimen was well-tolerated, with grade 3/4 neutropenia occurring in approximately two-thirds of the patients. No unexpected adverse events (AEs) were reported and the observed AEs were manageable. CONCLUSIONS: This large cohort phase 1b/2 study showed that Chi-CHOEP was well-tolerated with modest efficacy in previously untreated PTCL patients. |
format | Online Article Text |
id | pubmed-8330529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Compuscript |
record_format | MEDLINE/PubMed |
spelling | pubmed-83305292021-08-09 The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study Zhang, Wei Su, Liping Liu, Lihong Gao, Yuhuan Wang, Quanshun Su, Hang Song, Yuhuan Zhang, Huilai Shen, Jing Jing, Hongmei Wang, Shuye Cen, Xinan Liu, Hui Liu, Aichun Li, Zengjun Luo, Jianmin He, Jianxia Wang, Jingwen O’Connor, O. A. Zhou, Daobin Cancer Biol Med Original Article OBJECTIVE: To assess the efficacy and safety of the novel histone deacetylase inhibitor, chidamide, in combination with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (Chi-CHOEP) for untreated peripheral T-cell lymphoma (PTCL). METHODS: A prospective, multicenter, single arm, phase 1b/2 study was conducted. A total of 128 patients with untreated PTCL (18–70 years of age) were enrolled between March 2016 and November 2019, and treated with up to 6 cycles with the Chi-CHOEP regimen. In the phase 1b study, 3 dose levels of chidamide were evaluated and the primary endpoint was determination of the maximum-tolerated dose and recommended phase 2 dose (RP2D). The primary endpoint of the phase 2 study was 2-year progression-free survival (PFS). RESULTS: Fifteen patients were enrolled in the phase 1b study and the RP2D for chidamide was determined to be 20 mg, twice a week. A total of 113 patients were treated at the RP2D in the phase 2 study, and the overall response rate was 60.2%, with a complete response rate of 40.7%. At a median follow-up of 36 months, the median PFS was 10.7 months, with 1-, 2-, and 3-year PFS rates of 49.9%, 38.0%, and 32.8%, respectively. The Chi-CHOEP regimen was well-tolerated, with grade 3/4 neutropenia occurring in approximately two-thirds of the patients. No unexpected adverse events (AEs) were reported and the observed AEs were manageable. CONCLUSIONS: This large cohort phase 1b/2 study showed that Chi-CHOEP was well-tolerated with modest efficacy in previously untreated PTCL patients. Compuscript 2021-08-15 2021-08-15 /pmc/articles/PMC8330529/ /pubmed/33755379 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0413 Text en Copyright: © 2021, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0 (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Original Article Zhang, Wei Su, Liping Liu, Lihong Gao, Yuhuan Wang, Quanshun Su, Hang Song, Yuhuan Zhang, Huilai Shen, Jing Jing, Hongmei Wang, Shuye Cen, Xinan Liu, Hui Liu, Aichun Li, Zengjun Luo, Jianmin He, Jianxia Wang, Jingwen O’Connor, O. A. Zhou, Daobin The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study |
title | The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study |
title_full | The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study |
title_fullStr | The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study |
title_full_unstemmed | The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study |
title_short | The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study |
title_sort | combination of chidamide with the choep regimen in previously untreated patients with peripheral t-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330529/ https://www.ncbi.nlm.nih.gov/pubmed/33755379 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0413 |
work_keys_str_mv | AT zhangwei thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT suliping thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT liulihong thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT gaoyuhuan thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT wangquanshun thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT suhang thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT songyuhuan thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT zhanghuilai thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT shenjing thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT jinghongmei thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT wangshuye thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT cenxinan thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT liuhui thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT liuaichun thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT lizengjun thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT luojianmin thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT hejianxia thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT wangjingwen thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT oconnoroa thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT zhoudaobin thecombinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT zhangwei combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT suliping combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT liulihong combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT gaoyuhuan combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT wangquanshun combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT suhang combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT songyuhuan combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT zhanghuilai combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT shenjing combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT jinghongmei combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT wangshuye combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT cenxinan combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT liuhui combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT liuaichun combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT lizengjun combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT luojianmin combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT hejianxia combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT wangjingwen combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT oconnoroa combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study AT zhoudaobin combinationofchidamidewiththechoepregimeninpreviouslyuntreatedpatientswithperipheraltcelllymphomaaprospectivemulticentersinglearmphase1b2study |